AI Article Synopsis

  • The NY-ESO-1 gene, found on chromosome Xq28, is typically active only in germ cells but becomes expressed in various tumors, triggering immune responses in cancer patients; clinical trials are currently underway.
  • A related gene, LAGE-1, was discovered alongside NY-ESO-1, and a third gene, ESO3, has also been identified, located on the X chromosome with conserved genetic structures among the three genes but differing in expression patterns.
  • Mouse and rat versions of ESO3 (mESO3 and rESO3) have been identified, showing similar characteristics as human ESO3, including ubiquitous expression in tissues, while no equivalents for NY-ESO-1 or LAGE-1

Article Abstract

The NY-ESO-1 gene, located on chromosome Xq28, encodes a cancer/testis antigen in human. Normally expressed only in germ cells, NY-ESO-1 is activated in a wide range of human tumors, eliciting both antibody and cell-mediated immune responses in cancer patients. Clinical immunotherapeutic trials NY-ESO-1 gene products are now ongoing. A closely related gene, LAGE-1, was subsequently identified and shares similar biological features. By database search, we have identified a third member of the human NY-ESO-1 gene family. This gene, designated ESO3, is also located on the X chromosome, clustered with two exact copies of ESO1(NY-ESO-1) and one copy of ESO2(LAGE-1), within a approximately 400 kb segment. The exon-intron structures are conserved among ESO1-3. While ESO1 and ESO2(LAGE-1) share >80% protein sequence identity, homology between ESO3 and the other two members is lower (<50%). ESO3 is also distinctive in that, unlike ESO1 and 2 that are normally expressed only in testis, ESO3 messenger RNA (mRNA) is ubiquitously expressed in somatic tissues. In addition to ESO3, an intronless pseudogene highly homologous to ESO3 was found on chromosome 9, designated psiESO3.A search of the rodent databases identified mouse and rat counterparts of ESO3, named mESO3 and rESO3. mESO3 is similarly located on mouse X chromosome, with conserved exon-intron junctions. Protein sequence of mESO3 is 54% identical to ESO3 (70% identical at the conserved carboxyl end), and 32% to ESO1. mESO3 mRNA is also ubiquitously expressed in somatic tissues, as is rESO3. In addition, an intronless and presumably non-coding, copy of the mESO3, psimESO3, was identified on mouse chromosome 15. No counterpart of the ESO1 or 2 genes was found in rodents.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0378-1119(02)00879-xDOI Listing

Publication Analysis

Top Keywords

ny-eso-1 gene
16
gene family
8
located chromosome
8
gene
6
member ny-eso-1
4
family ubiquitously
4
ubiquitously expressed
4
expressed somatic
4
somatic tissues
4
tissues evolutionarily
4

Similar Publications

This study aims to investigate the expression of seven cancer testis antigens (MAGE-A1, MAGE-A4, MAGE-A10, MAGE-A11, PRAME, NY-ESO-1 and KK-LC-1) in pan squamous cell carcinoma and their prognostic value, thus assessing the potential of these CTAs as immunotherapeutic targets. The protein expression of these CTAs was evaluated by immunohistochemistry in 60 lung squamous cell carcinoma (LUSC), 62 esophageal squamous cell carcinoma (ESCA) and 62 head and neck squamous cell carcinoma (HNSC). The relationship between CTAs expression and progression-free survival (PFS) was assessed.

View Article and Find Full Text PDF

Generation of high avidity T cell receptors (TCRs) reactive to tumor-associated antigens (TAA) is impaired by tolerance mechanisms, which is an obstacle to effective T cell therapies for cancer treatment. NY-ESO-1, a human cancer-testis antigen, represents an attractive target for such therapies due to its broad expression in different cancer types and the restricted expression in normal tissues. Utilizing transgenic mice with a diverse human TCR repertoire, we isolated effective TCRs against NY-ESO-1 restricted to HLA-A*02:01.

View Article and Find Full Text PDF

The development of T cell receptor-engineered T cells (TCR-T) targeting intracellular antigens is a promising strategy for treating solid tumors; however, the mechanisms underlying their effectiveness remain poorly understood. In this study, we employed advanced techniques to investigate the functional state of T cells engineered with retroviral vectors to express a TCR specific for the NY-ESO-1 157-165 peptide in the HLA-A*02:01 context. Flow cytometry revealed a predominance of naïve T cells.

View Article and Find Full Text PDF

Novel pharmacotherapies for the treatment of liposarcoma: a comprehensive update.

Expert Opin Pharmacother

December 2024

Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.

Article Synopsis
  • * Recent literature has highlighted novel therapies in development for liposarcomas over the past five years, focusing on targeted therapies and immuno-oncology strategies.
  • * Advances in understanding liposarcoma subtypes have led to promising treatments like CDK4 and MDM2 inhibitors, as well as immune therapies, while the search for effective combination therapies and biomarkers for patient selection is still ongoing.
View Article and Find Full Text PDF
Article Synopsis
  • * Current treatments primarily involve surgical resection for localized cases, with chemotherapy and radiotherapy as adjuncts, while targeted therapies remain limited.
  • * There is a growing interest in exploring molecular characteristics of SS subtypes to identify new treatment targets, with innovative approaches including immune-based therapies and epigenetic modifiers being researched.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!